Literature DB >> 8026262

Prevalence and significance of anticardiolipin antibodies in Crohn's disease.

P Chamouard1, L Grunebaum, M L Wiesel, J M Freyssinet, B Duclos, J P Cazenave, R Baumann.   

Abstract

Crohn's disease is a chronic inflammatory bowel syndrome in which thrombotic complications occur in the active phase. Phospholipid-binding antibodies such as anticardiolipin antibodies and lupus anticoagulants have been shown to be associated with thrombosis. Their presence has been assessed in a group of 50 patients with Crohn's disease among whom 44 had active disease. The overall prevalence of anticardiolipin antibodies was about 22%, while none of these patients had lupus anticoagulant. Anticardiolipin antibodies have been observed in both active and quiescent CD and their presence does not seem to be related to the site of CD lesions. The presence of phospholipid-binding antibodies could be a sign of vascular alterations that are potentially thrombogenic per se, and their predictive value with respect to the specific inflammatory syndrome of Crohn's disease is discussed.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8026262     DOI: 10.1007/bf02088055

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  35 in total

1.  High endothelin-1 immunoreactivity in Crohn's disease and ulcerative colitis.

Authors:  S H Murch; C P Braegger; W C Sessa; T T MacDonald
Journal:  Lancet       Date:  1992-02-15       Impact factor: 79.321

2.  Anticardiolipin antibodies: a study of frequency in TIA and stroke.

Authors:  D C Hess; J Krauss; R J Adams; F T Nichols; D Zhang; H A Rountree
Journal:  Neurology       Date:  1991-04       Impact factor: 9.910

Review 3.  Warner-Lambert/Parke-Davis award lecture. Cytokine-mediated activation of vascular endothelium. Physiology and pathology.

Authors:  J S Pober
Journal:  Am J Pathol       Date:  1988-12       Impact factor: 4.307

Review 4.  Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance.

Authors:  P E Love; S A Santoro
Journal:  Ann Intern Med       Date:  1990-05-01       Impact factor: 25.391

Review 5.  Blood cell membranes and haemostasis.

Authors:  R F Zwaal; H C Hemker
Journal:  Haemostasis       Date:  1982

6.  Effect of the lupus anticoagulant on endothelial fibrinolytic activity in vitro.

Authors:  R B Francis; S Neely
Journal:  Thromb Haemost       Date:  1989-04-25       Impact factor: 5.249

7.  Modulation of endothelial cell functions by different molecular species of interleukin 1.

Authors:  E Dejana; F Breviario; A Erroi; F Bussolino; L Mussoni; M Gramse; G Pintucci; B Casali; C A Dinarello; J Van Damme
Journal:  Blood       Date:  1987-02       Impact factor: 22.113

8.  Disturbed fibrinolysis in patients with inflammatory bowel disease. A study in blood plasma, colon mucosa, and faeces.

Authors:  E de Jong; R J Porte; E A Knot; J H Verheijen; J Dees
Journal:  Gut       Date:  1989-02       Impact factor: 23.059

9.  Hemostatic alterations in inflammatory bowel disease: response to therapy.

Authors:  A M Lake; J Q Stauffer; M J Stuart
Journal:  Am J Dig Dis       Date:  1978-10

10.  Modulation of endothelial cell hemostatic properties by tumor necrosis factor.

Authors:  P P Nawroth; D M Stern
Journal:  J Exp Med       Date:  1986-03-01       Impact factor: 14.307

View more
  11 in total

1.  Hyperhomocysteinemia in Greek patients with inflammatory bowel disease.

Authors:  I E Koutroubakis; E Dilaveraki; I G Vlachonikolis; E Vardas; G Vrentzos; E Ganotakis; I A Mouzas; A Gravanis; D Emmanouel; E A Kouroumalis
Journal:  Dig Dis Sci       Date:  2000-12       Impact factor: 3.199

2.  Anti-cardiolipin antibodies in patients with inflammatory bowel disease.

Authors:  B W Aichbichler; W Petritsch; G A Reicht; H H Wenzl; A J Eherer; T A Hinterleitner; P Auer-Grumbach; G J Krejs
Journal:  Dig Dis Sci       Date:  1999-04       Impact factor: 3.199

3.  Crohn's and Behçet's disease association presenting with superior vena cava thrombosis.

Authors:  Aydin Seref Köksal; Ibrahim Ertugrul; Selçuk Dişibeyaz; Muharrem Tola; Sabite Kacar; Mehmet Arhan; Fatih Aydin; Aysel Ulker
Journal:  Dig Dis Sci       Date:  2005-09       Impact factor: 3.199

4.  Reduced free protein S levels in patients with inflammatory bowel disease: prevalence, clinical relevance, and role of anti-protein S antibodies.

Authors:  S Saibeni; M Vecchi; C Valsecchi; E M Faioni; C Razzari; R de Franchis
Journal:  Dig Dis Sci       Date:  2001-03       Impact factor: 3.199

5.  Antiphospholipid antibodies in inflammatory bowel disease.

Authors:  J C Souto; M Borrell; J Fontcuberta; M Roca
Journal:  Dig Dis Sci       Date:  1995-07       Impact factor: 3.199

6.  Prevalence, significance and predictive value of antiphospholipid antibodies in Crohn's disease.

Authors:  Nora Sipeki; Laszlo Davida; Eszter Palyu; Istvan Altorjay; Jolan Harsfalvi; Peter Antal Szalmas; Zoltan Szabo; Gabor Veres; Zakera Shums; Gary L Norman; Peter L Lakatos; Maria Papp
Journal:  World J Gastroenterol       Date:  2015-06-14       Impact factor: 5.742

7.  Anti-cardiolipin and anti-beta2-glycoprotein I antibodies in patients with inflammatory bowel disease.

Authors:  I E Koutroubakis; E Petinaki; E Anagnostopoulou; H Kritikos; I A Mouzas; E A Kouroumalis; O N Manousos
Journal:  Dig Dis Sci       Date:  1998-11       Impact factor: 3.199

Review 8.  Structural brain lesions in inflammatory bowel disease.

Authors:  Can Dolapcioglu; Hatice Dolapcioglu
Journal:  World J Gastrointest Pathophysiol       Date:  2015-11-15

9.  Activated protein C resistance, thrombophilia, and inflammatory bowel disease.

Authors:  M A Heneghan; B Cleary; M Murray; T A O'Gorman; C F McCarthy
Journal:  Dig Dis Sci       Date:  1998-06       Impact factor: 3.199

Review 10.  Systemic lupus erythematosus complicated by Crohn's disease: a case report and literature review.

Authors:  Hiroyuki Yamashita; Yo Ueda; Hoshimi Kawaguchi; Akitake Suzuki; Yuko Takahashi; Hiroshi Kaneko; Toshikazu Kano; Akio Mimori
Journal:  BMC Gastroenterol       Date:  2012-12-05       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.